A hemostatic powder comprises a chitosan salt together with at least one inert material. The disclosure also relates to hemostatic powders into which fluid penetrability is 0.5 cm or more within 1 minute. At least one medical surfactant may optionally be included. The hemostatic powders may be incorporated into wound dressings.

Claims

44 · 3 independent · depth 4

44 granted claims

›1.independentA hemostatic powder comprising a chitosan salt together with at least one inert material.+20

›2.↳ 1A hemostatic powder according to claim 1, wherein the chitosan salt comprises one or more of the group consisting of: chitosan acetate, chitosan lacta…d2+1

›4.↳ 1A hemostatic powder according to claim 1, wherein the chitosan salt constitutes at least 5% by weight of the hemostatic powder.d2+1

›6.↳ 1A hemostatic powder according to claim 1, wherein the at least one inert material comprises one or more of the group consisting of: cellulose, fumed s…d2

›7.↳ 1A hemostatic powder according to claim 1, wherein the at least one inert material constitutes at least 30% by weight of the hemostatic powder.d2

›8.↳ 1A hemostatic powder according to claim 1, wherein the chitosan salt comprises particles that will pass through a 5 mesh screen but be retained by a 80…d2+1

›10.↳ 1A hemostatic powder according to claim 1, wherein the particle size of the chitosan salt and the particle size of the at least one inert material are …d2

›11.↳ 1A hemostatic powder according to claim 1, wherein the hemostatic powder further comprises at least one medical surfactant.d2+4

›16.↳ 1A hemostatic powder according to claim 1, wherein the hemostatic powder has a pH of from 3.5 to 6.d2

›37.↳ 1A hemostatic wound dressing comprising a hemostatic powder according to claim 1.d2+2

›43.↳ 1A method of stemming blood flow, including the steps of: applying to a wound area a hemostatic powder according to claim 1; and applying constant pres…d2+1

›17.independentA hemostatic powder comprising a chitosan salt, wherein fluid penetrability into the hemostatic powder is 0.5 cm or more within 1 minute.+19

›18.↳ 17A hemostatic powder according to claim 17, wherein fluid penetrability into the hemostatic powder is 1 cm or more within 1 minute.d2+1

›20.↳ 17A hemostatic powder according to claim 17, wherein the hemostatic powder further comprises at least one inert material.d2+2

›21.↳ 17A hemostatic powder according to claim 17, wherein the chitosan salt comprises one or more of the group consisting of: chitosan acetate, chitosan lact…d2+1

›23.↳ 17A hemostatic powder according to claim 17, wherein the chitosan salt constitutes at least 5% by weight of the hemostatic powder.d2+1

›27.↳ 17A hemostatic powder according to claim 17, wherein the chitosan salt comprises particles that will pass through a 5 mesh screen but be retained by a 8…d2+1

›29.↳ 17A hemostatic powder according to claim 17, wherein the particle size of the chitosan salt and the particle size of the at least one inert material are…d2

›30.↳ 17A hemostatic powder according to claim 17, wherein the hemostatic powder further comprises at least one medical surfactant.d2+6

›40.independentA method of manufacturing a hemostatic powder, comprising the steps of: preparing a mixture of chitosan and an acid in a solvent in which the chitosan…+2

Classifications

3 codes

IPC · International Patent Classification

Section A — Human necessities

A01N43/04

USPC · US Patent Classification

514/55514/54

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

4.8 y

1,764 days filing → grant

Office actions

non-final + final

Responses

1 RCE

Examiner

Patrick Lewis

art unit 1623 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 5 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20090186851 A1	23 Jul 2009

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.